POST Online Media Lite Edition



 

NEWLY REPORTED COVID-19 CASES IN LAST 24h (3.4.2021, 9:55am CET, WHO):   U.S. 57,831    India 17,407    Brazil 59,925    Russia 10,535    The United Kingdom 6,391    France 22,148    Spain 2,662    Italy 17,063    Turkey 11,837    Germany 9,019    Columbia 4,339    Argentina 7,855    Mexico 7,913    Poland 15,698    Iran 8,525    Ukraine 7,235    Indonesia 6,808    Peru 5,358    Czechia 16,816    The Netherlands 4,032    Canada 2,714    Chile 3,040    Romania 3,950    Israel 4,809    Iraq 5,173    Sweden 2,843    Pakistan 1,388    Philippines 1,781    Serbia 4,157    Austria 2,648    Hungary 4,211    Japan 1,192    Jordan 5,335    United Arab Emirates 2,692    Lebanon 3,463    Slovakia 3,357    Malaysia 1,745    Ecuador 2,747    Bulgaria 2,403    Palestine 2,017    Kuwait 1,409    Greece 1,312    Moldova 1,400    Paraguay 1,082    Estonia 1,454    China 27    Singapore 23    New Zealand 6    Australia 10    South Korea 424   

Cuba's medicine will be tested in U.S., Mexico and Brazil

Christian Fernsby |
The monoclonal antibody Itolizumab received authorization to start a phase III clinical trial in coronavirus patients in the U.S., Mexico and Brazil, reported Cuba's Center for Molecular Immunology (CIM).

Article continues below




Developed by that institution in collaboration with the India's BIOCON company, this trial will consolidate the scientific pieces of evidence that supports the effective inclusion of the drug in the Cuba's protocol for the coronavirus treatment, warns the CIM on Twitter.

Winner of one of the National Awards of the Cuban Academy of Sciences in 2014, in the Biomedical Sciences category, the product has an anti inflammatory and immuno regulatory effect.

Recently, Cuban researchers also shared on social networks an article published in the Gerontology Journal about the country's experience of Itolizumab's use in elderly coronavirus patients.

According to the text, the study combined the timely use of this monoclonal antibody with other antiviral and anticoagulant therapies to reduce the worsening of coronavirus and mortality.

Experts assured that this innovative product of Cuban biotechnology allowed reducing the number of critical patients.


What to read next

Cuba presents second vaccine candidate against coronavirus for evaluation
More children with ADHD could benefit from behavior therapy
Miami-Dade mosquitoes test positive for Zika